Literature DB >> 21368756

Benzodiazepine-like hypnotics and the associated risk of road traffic accidents.

L Orriols1, P Philip, N Moore, A Castot, B Gadegbeku, B Delorme, M Mallaret, E Lagarde.   

Abstract

The aim of the study was to investigate the association between the use of benzodiazepine or benzodiazepine-like hypnotics and the risk of road traffic accidents. Data from three French national databases were matched: the health-care insurance database, police reports, and the police database of injury-related traffic accidents. A total of 72,685 drivers involved in injury-related road traffic accidents in France, from 2005 to 2008, were included in the study. The risk of being responsible for a traffic accident was higher in users of benzodiazepine hypnotics (odds ratio (OR) = 1.39 (1.08-1.79)) and in the 155 drivers to whom a dosage of more than one pill of zolpidem a day had been dispensed during the 5 months before the collision (OR = 2.46 (1.70-3.56)). No association was found between the use of zopiclone and risk of traffic accidents. Although this study did not find any association between the use of zolpidem as recommended and causation of traffic accidents, the potential risk related to possible abuse of the drug and risky driving behaviors should be further investigated. The results related to benzodiazepine hypnotics are consistent with those of previous studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21368756     DOI: 10.1038/clpt.2011.3

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  41 in total

1.  Use of benzodiazepines and z-drugs not compliant with guidelines and associated factors: a population-based study.

Authors:  Arnaud Panes; Antoine Pariente; Anne Bénard-Laribière; Régis Lassalle; Caroline Dureau-Pournin; Simon Lorrain; Marie Tournier; Annie Fourrier-Réglat
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2018-12-11       Impact factor: 5.270

2.  Prescription of Zolpidem and the Risk of Fatal Motor Vehicle Collisions: A Population-Based, Case-Crossover Study from South Korea.

Authors:  Bo Ram Yang; Ye-Jee Kim; Mi-Sook Kim; Sun-Young Jung; Nam-Kyong Choi; Byungkwan Hwang; Byung-Joo Park; Joongyub Lee
Journal:  CNS Drugs       Date:  2018-06       Impact factor: 5.749

Review 3.  Pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol).

Authors:  Lingtak-Neander Chan; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

4.  Long-term sedative use among community-dwelling adults: a population-based analysis.

Authors:  Deirdre Weymann; Emilie J Gladstone; Kate Smolina; Steven G Morgan
Journal:  CMAJ Open       Date:  2017-03-03

5.  Fatal crashes from drivers testing positive for drugs in the U.S., 1993-2010.

Authors:  Fernando A Wilson; Jim P Stimpson; José A Pagán
Journal:  Public Health Rep       Date:  2014 Jul-Aug       Impact factor: 2.792

6.  Effects of pregabalin in patients with hypnotic-dependent insomnia.

Authors:  Youg Won Cho; Mei Ling Song
Journal:  J Clin Sleep Med       Date:  2014-05-15       Impact factor: 4.062

7.  Use of benzodiazepines and related drugs in Manitoba: a population-based study.

Authors:  Silvia Alessi-Severini; James M Bolton; Murray W Enns; Matthew Dahl; David M Collins; Dan Chateau; Jitender Sareen
Journal:  CMAJ Open       Date:  2014-10-01

Review 8.  In the Zzz zone: the effects of Z-drugs on human performance and driving.

Authors:  Naren Gunja
Journal:  J Med Toxicol       Date:  2013-06

Review 9.  Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review.

Authors:  Toni M Rudisill; Motao Zhu; George A Kelley; Courtney Pilkerton; Brandon R Rudisill
Journal:  Accid Anal Prev       Date:  2016-08-29

10.  Pharmacological Interactions between the Dual Orexin Receptor Antagonist Daridorexant and Ethanol in a Double-Blind, Randomized, Placebo-Controlled, Double-Dummy, Four-Way Crossover Phase I Study in Healthy Subjects.

Authors:  Benjamin Berger; Sander Brooks; Rob Zuiker; Muriel Richard; Clemens Muehlan; Jasper Dingemanse
Journal:  CNS Drugs       Date:  2020-11-18       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.